FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

Impact · against what's priced in

The FDA's first-line approval for Jaypirca provides a modest catalyst for Eli Lilly by expanding its oncology footprint, though it remains a minor driver compared to the GLP-1 portfolio. For Johnson & Johnson, the approval increases competitive pressure on Imbruvica, potentially hindering the acceleration needed to reach its $50 billion oncology target.

LLY+0.20: Challenges what's priced in
The price assumes

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

What matters in this story

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

What matters in this story

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

How each ticker is affected

Connected tickers

Track these names every morning.

Alpha Tau to Participate in October Investor Conferences

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

What matters in this story

Next reads from the same story arc

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting

What matters in this story

Next reads from the same story arc

Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions

How each ticker is affected

Connected tickers

Track these names every morning.

Alpha Tau to Participate in October Investor Conferences

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call